艾迪药业：2025年净利润亏损1973.37万元

Core Viewpoint - Eddie Pharmaceuticals reported a total revenue of 721 million yuan for the fiscal year 2025, representing a year-on-year increase of 72.49%. However, the company incurred a net loss of 19.73 million yuan, an improvement from a loss of 141 million yuan in the same period last year [1]. Group 1: Financial Performance - The increase in total revenue is attributed to higher income from innovative anti-HIV drugs and the operational data from the merger with Nanda Pharmaceuticals [1]. - The gross profit from core business increased by approximately 255 million yuan compared to the same period last year [1]. - The net loss decreased significantly from 141 million yuan to 19.73 million yuan, indicating improved financial health [1]. Group 2: Expenses and Costs - Sales expenses rose by approximately 92 million yuan compared to the previous year due to increased efforts in new drug promotion and the merger with Nanda Pharmaceuticals [1]. - Asset impairment losses decreased by about 48 million yuan compared to the same period last year, reflecting a stabilization in market expansion and expectations [1].